Glioblastoma: Prognostic Factors and Predictive Response to Radio and Chemotherapy-Reference-Cited by-同舟云学术

Glioblastoma: Prognostic Factors and Predictive Response to Radio and Chemotherapy

Published:2020-06-04 Issue:17 Volume:27 Page:2814-2825
ISSN:0929-8673
Container-title:Current Medicinal Chemistry
language:en
Short-container-title:CMC

Author:

Fiorica Francesco¹,Colella Maria²,Taibi Rosaria³,Bonetti Andrea⁴,Giuliani Jacopo⁴,Perrone Maria Sole⁵,Missiroli Sonia⁵,Giorgi Carlotta⁶

Affiliation:

1. Department of Radiation Oncology, AULSS 9 Scaligera, Verona, Italy

2. Department of Radiation Oncology, University Hospital Ferrara, Ferrara, Italy

3. Department of Medical Oncology, National Cancer Institute, Aviano (PN), Italy

4. Department of Oncology, AULSS 9 Scaligera, Verona, Italy

5. Department of Medical Sciences, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy

6. Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy

Abstract

: Glioblastoma multiforme (GBM) is characterized by poor prognosis despite an aggressive therapeutic strategy. In recent years, many advances have been achieved in the field of glioblastoma biology. : Here we try to summarize the main clinical and biological factors impacting clinical prognostication and therapy of GBM patients. From that standpoint, hopefully, in the near future, personalized therapies will be available.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry

Reference80 articles.

1. Baldin E.; Testoni S.; de Pasqua S.; Ferro S.; Albani F.; Baruzzi A.; D’Alessandro R.; Incidence of neuroepithelial primary brain tumors among adult population of Emilia-Romagna Region, Italy. Neurol Sci PERNO study group2017,38(2),255-262

2. Stupp R.; Hegi M.E.; Mason W.P.; van den Bent M.J.; Taphoorn M.J.B.; Janzer R.C.; Ludwin S.K.; Allgeier A.; Fisher B.; Belanger K.; Hau P.; Brandes A.A.; Gijtenbeek J.; Marosi C.; Vecht C.J.; Mokhtari K.; Wesseling P.; Villa S.; Eisenhauer E.; Gorlia T.; Weller M.; Lacombe D.; Cairncross J.G.; Mirimanoff R.O.; Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups National Cancer Institute of Canada Clinical Trials Group2009,10(5),459-466

3. Louis D.N.; Ohgaki H.; Wiestler O.D.; Cavenee W.K.; Burger P.C.; Jouvet A.; Scheithauer B.W.; Kleihues P.; The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007,114(2),97-109

4. Theeler B.J.; Gilbert M.R.; Advances in the treatment of newly diagnosed glioblastoma. BMC Med 2015,13,293

5. Scherer H.J.; Cerebral astrocytomas and their derivatives. Am J Cancer 1940,40(2),159-198

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Updated Understanding of the Role of YAP in Driving Oncogenic Responses;Cancers;2021-06-21